16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
CNS disorder specialist Intra-Cellular Therapies has announced positive to-pline results from Study 502, evaluating its depression candidate lumateperone. 19 June 2024
US chemoproteomics start-up Belharra Therapeutics, has entered into a strategic collaboration with French pharma major Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases. 19 June 2024
The Swiss company Swixx BioPharma has stopped the supplies of Humalog insulin (insulin lispro) to Russia due to the decision of its manufacturer, the American pharma major Eli Lilly, The Pharma Letter’s local correspondent reports. 19 June 2024
In Europe, revised rules for the Clinical Trials Information System (CTIS) are now applicable, offering faster access to clinical trial information. 18 June 2024
The Russian pharmaceutical market is undergoing a large-scale transformation, as the share of foreign drugs is steadily declining due to acceleration of processes of import substitution, reports The Pharma Letter’s local correspondent. 18 June 2024
Shares of US drug developer Aerovate Therapeutics plummeted 93% yesterday and were down a further 6.7% at $1.54 pre-market, after it revealed it would scrap a late-stage development of its lead investigational candidate. 18 June 2024
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Johnson & Johnson continues to be the world's most valuable and strongest pharmaceutical brand, according to a new report by Brand Finance. 18 June 2024
Takeda, Japan’s largest drugmaker, today announced mixed top-line data from its SKYLINE and SKYWAY Phase III trials outcomes for its drug soticlestat. 17 June 2024
Japanese drugmaker Mitsubishi Tanabe Pharma (MTPC) has entered into an agreement with Paris, France-based Ethypharm for the transfer of the business of the selective antithrombin agent, argatroban monohydrate in Europe. 17 June 2024
"There is a need for good conditions for entrepreneurs in Denmark. It is an important piece if we hope to maintain and expand our global position, not least within life science and biotech," says Ida Sofie Jensen, chief executive of the Danish Pharmaceutical Industry Association, Lif. 17 June 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Augtyro (repotrectinib), from Bristol Myers Squibb), for a new indication. 14 June 2024
Bladder cancer specialist UroGen Pharma saw its shares close up nearly 38% at $17.50 yesterday, after it shared positive trial results on its lead pipeline candidate UGN-102, an innovative formulation of mitomycin. 14 June 2024
As the UK heads for a general election next month, the Association of the British Pharmaceutical Industry (ABPI) today assessed the Labour Party manifesto, having yesterday appraised the UK Conservative pledges. 13 June 2024
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Johnson & Johnson says it has “grave concern” for the availability of future innovative mental health treatments in England, following a decision by National Institute for Health and Care Excellence (NICE) to not re-appraise Spravato (esketamine nasal spray) for treatment-resistant depression in England 13 June 2024
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration to improve glycemic control in children with type-2 diabetes (T2D). 13 June 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.